Pandey Sagar, Tan Ernestine Faye S, Bellamkonda Amulya, Aryal Binit, Karki Sailesh, Boddu Gouthami, Sapkota Ranjit, Changela Madhav, Kalavar Madhumati
Internal Medicine, One Brooklyn Health System/Interfaith Medical Center, Brooklyn, USA.
Hematology and Oncology, One Brooklyn Health System/Interfaith Medical Center, Brooklyn, USA.
Cureus. 2024 Feb 19;16(2):e54463. doi: 10.7759/cureus.54463. eCollection 2024 Feb.
Acute painful vaso-occlusive crisis (VOC) is the common presentation of sickle cell disease (SCD) leading to emergency room visits, admissions, morbidity, mortality, and negative impacts on quality of life. Among various treatment approaches commonly employed to manage the condition, intravenous (IV) hydration is also frequently used in emergency and inpatient settings. Although helpful to overcome dehydration, IV hydration often leads to adverse outcomes like fluid overload, pulmonary edema, increased length of stay, transfer to intensive care unit, new oxygen requirement, etc. Small-scale retrospective studies are conducted to study the outcomes of IV hydration but have failed to conclusively demonstrate its benefits as well as choice of IV fluids, rate of IV fluid replacement, etc. We conduct this review as an attempt to summarize the available evidence on the role and utility of IV hydration in sickle cell crises along with reported adverse outcomes.
急性疼痛性血管闭塞危象(VOC)是镰状细胞病(SCD)的常见表现,可导致急诊就诊、住院、发病、死亡以及对生活质量产生负面影响。在常用于管理该病症的各种治疗方法中,静脉补液在急诊和住院环境中也经常使用。尽管有助于克服脱水,但静脉补液常常导致诸如液体超负荷、肺水肿、住院时间延长、转至重症监护病房、需要新的吸氧等不良后果。开展了小规模回顾性研究以探究静脉补液的效果,但未能确凿地证明其益处以及静脉补液的选择、静脉补液替代率等。我们进行此项综述,旨在总结关于静脉补液在镰状细胞危象中的作用和效用以及所报告不良后果的现有证据。